One Year After the Lykos Rejection

What happened

A year after the FDA declined to approve Lykos Therapeutics’ MDMA-assisted therapy for PTSD, the picture is starting to settle. The CEO has stepped down, an interim is in place from outside the psychedelic space, and the company has cut about 75 percent of its headcount. Co-founder and longtime advocate Rick Doblin has stepped off the board. The FDA’s full Complete Response Letter is now public — itself a milestone for a category that has historically operated with less transparency than the rest of pharma.

The retrospective coverage from psychedelic trade press — Psychedelic Alpha’s one-year reflection is the best of the batch — converges on a similar read: the rejection forced a reckoning the field had been postponing about blinding, expectancy effects, and the difficulty of running a controlled trial on a substance with profoundly noticeable acute effects.

Why this matters

The pragmatic effect is that other psychedelic developers — Compass Pathways on psilocybin, Lykos on a path back, MindMed, Atai, Usona — are pivoting to more conventional Phase III rigor: larger samples, more careful blinding, attention to therapist effects, and explicit handling of post-trial expectancy. The field is becoming, by necessity, less exuberant and more methodical.

This is not a substance use disorder story directly. But it sits adjacent to one. Psychedelic-assisted therapy has been frequently floated as a treatment direction for substance use disorders, particularly alcohol and tobacco — there are real, peer-reviewed signals, including Bogenschutz on psilocybin for AUD. The pace at which that work matures is now downstream of the post-Lykos rigor reset.

For founders and operators in the broader recovery space, the operational read is straightforward: investor screening is now actively filtering for “Pear / Lykos-style hype risk.” Boring, pragmatic, payer-aligned models look better in 2026 than they did in 2024. That is a tailwind for navigation infrastructure and for evidence-based pharmacotherapy. It is a headwind for narrative-led breakthrough plays.

If you or someone you love is in crisis, call or text 988.